The effects of statins on blood pressure in normotensive or hypertensive subjects - A meta-analysis of randomized controlled trials

被引:34
作者
Banach, Maciej [1 ]
Nikfar, Shekoufeh [2 ,3 ]
Rahimi, Roja [4 ,5 ]
Bielecka-Dabrowa, Agata [1 ]
Pencina, Michael J. [6 ]
Mikhailidis, Dimitri P. [7 ]
Narkiewicz, Krzysztof [8 ]
Rysz, Jacek [9 ]
Ray, Kausik K. [10 ]
Abdollahi, Mohammad [4 ,5 ]
机构
[1] Med Univ Lodz, Dept Hypertens, PL-90549 Lodz, Poland
[2] Univ Tehran Med Sci, Fac Pharm, Dept Pharmacoecon & Pharmaceut Adm, Tehran, Iran
[3] Minist Hlth & Med Educ, Food & Drug Lab Res Ctr, Tehran, Iran
[4] Univ Tehran Med Sci, Fac Pharm, Tehran, Iran
[5] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr, Tehran, Iran
[6] Boston Univ, Harvard Clin Res Inst, Dept Biostat, Boston, MA 02215 USA
[7] UCL, Sch Med, Dept Clin Biochem, London W1N 8AA, England
[8] Med Univ Gdansk, Dept Hypertens & Diabetol, Gdansk, Poland
[9] Med Univ Lodz, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
[10] St Georges Univ London, Cardiovasc Sci Res Ctr, London, England
关键词
Blood pressure; Hypertension; Meta-analysis; Statins; Therapy; COA REDUCTASE INHIBITOR; NITRIC-OXIDE SYNTHASE; LIPID-LOWERING ARM; HYPERCHOLESTEROLEMIC PATIENTS; ENDOTHELIAL FUNCTION; DOUBLE-BLIND; ATORVASTATIN; CHOLESTEROL; SIMVASTATIN; PRAVASTATIN;
D O I
10.1016/j.ijcard.2013.03.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this meta-analysis was to investigate whether statin therapy is associated with blood pressure (BP)-lowering in patients with or without hypertension. Background: The beneficial effects of statins on the cardiovascular system may in part be related to effects beyond lipid-lowering. It has been suggested that statins may reduce BP; however the available data are still ambiguous and often conflicting. Methods: Data from Scopus, PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials for the years 1966-January 2012 were searched for studies that investigated the effect of statins on BP in normotensive or in hypertensive subjects. We included all randomized controlled clinical trials that investigated this effect. Changes in systolic and diastolic BP were the key outcomes of interest. Results: The final analysis included 18 trials and 5628 subjects (4692 normotensive and 936 hypertensive patients) randomized to receive either statins or placebo. The weighted mean difference of systolic (Delta SBP) and diastolic blood pressure (Delta DBP) in normotensive patients for the 11 statin trials included were 0.03 (95% CI: -0.95-1.02; p = 0.95) and -0.28 (95% CI: -0.80-0.24; p = 0.29), respectively. For hypertensive patients treated with statins (8 trials) the weighted mean difference of Delta SBP and Delta DBP were 1.45 (95% CI: -0.49-3.39; p = 0.14) and -1.32 (95% CI: -3.93-1.28; p = 0.32) respectively. Conclusions: Despite previous suggestions statin therapy in normotensive or hypertensive patients does not lead to significant reductions in systolic or diastolic BP. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:2816 / 2824
页数:9
相关论文
共 47 条
[1]   Effects of statins on renal function [J].
Agarwal, Rajiv .
MAYO CLINIC PROCEEDINGS, 2007, 82 (11) :1381-1390
[2]   Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model [J].
Aydin, Unal ;
Ugurlucan, Murat ;
Gungor, Funda ;
Ziyade, Sedat ;
Inan, Bekir ;
Banach, Maciej ;
Kalko, Yusuf ;
Yasar, Tahsin .
ANGIOLOGY, 2009, 60 (03) :370-377
[3]  
Bak AAA, 1998, J INTERN MED, V244, P371
[4]   Intense cholesterol lowering therapy with a HWG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes -: A multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial [J].
Balletshofer, BM ;
Goebbel, S ;
Rittig, K ;
Enderle, M ;
Schmölzer, I ;
Wascher, TC ;
Pap, AF ;
Westermeier, T ;
Petzinna, D ;
Matthaei, S ;
Häring, HU .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (06) :324-330
[5]  
Banach M, 2009, MED SCI MONITOR, V15, pMS1
[6]   Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia [J].
Borghi, C ;
Prandin, MG ;
Costa, FV ;
Bacchelli, S ;
Degli Esposti, D ;
Ambrosioni, E .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :549-555
[7]   Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet [J].
Derosa, G ;
Mugellini, A ;
Ciccarelli, L ;
Fogari, R .
CLINICAL THERAPEUTICS, 2003, 25 (04) :1107-1122
[8]   Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial [J].
Ferreira, G. A. ;
Navarro, T. P. ;
Telles, R. W. ;
Andrade, L. E. C. ;
Sato, E. I. .
RHEUMATOLOGY, 2007, 46 (10) :1560-1565
[9]   Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia [J].
Glorioso, N ;
Troffa, C ;
Filigheddu, F ;
Dettori, F ;
Soro, A ;
Parpaglia, PP ;
Collatina, S ;
Pahor, M .
HYPERTENSION, 1999, 34 (06) :1281-1286
[10]   Statins in patients with chronic kidney disease: why, who and when? [J].
Gluba, Anna ;
Rysz, Jacek ;
Banach, Maciej .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (16) :2665-2674